Polaris Venture Management Co. V L.L.C. held its position in Genocea Biosciences Inc. (NASDAQ:GNCA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,968,606 shares of the company’s stock at the end of the second quarter. Genocea Biosciences makes up 8.7% of Polaris Venture Management Co. V L.L.C.’s investment portfolio, making the stock its 4th largest position. Polaris Venture Management Co. V L.L.C. owned about 0.07% of Genocea Biosciences worth $8,071,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GNCA. Schonfeld Strategic Advisors LLC purchased a new position in Genocea Biosciences during the first quarter valued at $565,000. Jacobs Levy Equity Management Inc. purchased a new position in Genocea Biosciences during the first quarter valued at $662,000. Geode Capital Management LLC raised its position in Genocea Biosciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 136,990 shares of the company’s stock valued at $1,060,000 after buying an additional 1,743 shares during the last quarter. State Street Corp raised its position in Genocea Biosciences by 11.9% in the first quarter. State Street Corp now owns 291,020 shares of the company’s stock valued at $2,256,000 after buying an additional 30,920 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in Genocea Biosciences by 37.0% in the first quarter. Franklin Resources Inc. now owns 2,886,600 shares of the company’s stock valued at $22,342,000 after buying an additional 779,400 shares during the last quarter. 56.49% of the stock is currently owned by institutional investors and hedge funds.
Genocea Biosciences Inc. (NASDAQ:GNCA) traded down 4.52% during mid-day trading on Friday, hitting $4.01. 417,826 shares of the stock were exchanged. Genocea Biosciences Inc. has a 1-year low of $2.56 and a 1-year high of $8.07. The company’s market capitalization is $113.62 million. The stock has a 50 day moving average price of $5.11 and a 200 day moving average price of $4.71.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.05. Genocea Biosciences had a negative return on equity of 47.87% and a negative net margin of 5,121.17%. On average, equities analysts anticipate that Genocea Biosciences Inc. will post ($1.63) earnings per share for the current fiscal year.
Several research firms recently weighed in on GNCA. Needham & Company LLC reissued a “buy” rating and set a $15.00 price objective on shares of Genocea Biosciences in a research note on Thursday, September 29th. Piper Jaffray Cos. reduced their price objective on shares of Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, September 29th. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a research note on Monday, August 8th. Finally, Zacks Investment Research lowered shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, July 6th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $12.35.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Want to see what other hedge funds are holding GNCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genocea Biosciences Inc. (NASDAQ:GNCA).
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.